Référentiel des médicaments
Sacituzumab govitecan
Sacituzumab govitecan is a medicine in the class oncology. It is used for breast cancer.
- Classe médicamenteuse: Oncology
- Indications: breast cancer
Dernière mise à jour Sources: US FDA label
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Oncology
- Code ATC
- L01FX06
- Formes courantes
- poudre
- Dosages courants
- 180 mg
- Interactions connues
- 2 (Contre-indiquée: 1 · Majeure: 1)
- Noms commerciaux
- 2
- Pays et marchés
- 2
Indications
Mécanisme d'action
Trop-2-directed antibody-drug conjugate. The humanized antibody binds Trop-2-expressing cancer cells and is internalized, releasing SN-38, a topoisomerase I inhibitor. SN-38 prevents re-ligation of single strand breaks, causing DNA damage, apoptosis and cell death.
Posologie adulte habituelle (résumé de la notice)
Triple-negative breast cancer or HR-positive/HER2-negative breast cancer: 10 mg/kg IV infusion on Days 1 and 8 of each 21-day cycle, as a single agent or with pembrolizumab; continue until disease progression or unacceptable toxicity; do not exceed 10 mg/kg
Grossesse et allaitement
- Grossesse
- Unsafe Can cause birth defects or embryo-fetal death: it contains SN-38, a genotoxic drug that targets dividing cells. No human or animal reproduction data. Check pregnancy status; use effective contraception during treatment and for 6 months after (men: 3 months).
- Allaitement
- Unsafe No human milk data. The antibody part is large and poorly absorbed, but the SN-38 payload may enter milk. US label: do not breastfeed during treatment and for 1 month after the last dose.
Effets indésirables signalés
- Decreased leukocyte count
- Decreased neutrophil count
- Decreased hemoglobin
- Nausea
- Diarrhea
- Fatigue
Mises en garde encadrées
- Can cause severe, life-threatening or fatal neutropenia. Withhold for ANC below 1500/mm3 or neutropenic fever; monitor blood counts; give primary G-CSF prophylaxis to patients at increased risk of febrile neutropenia; treat febrile neutropenia with anti-infectives without delay. Can cause severe diarrhea: monitor, give fluids and electrolytes, evaluate for infection and start loperamide; if severe, withhold until ≤ Grade 1 and reduce subsequent doses.
Contre-indications
- Severe hypersensitivity reaction to TRODELVY.
Précautions particulières
- Neutropenia occurred in 64% of patients (Grade 3-4 in 48%); monitor ANC and give G-CSF prophylaxis to patients at increased risk.
- Severe diarrhea; evaluate for infection and start loperamide; fluid and electrolyte replacement.
- Serious hypersensitivity and infusion-related reactions including anaphylaxis; premedicate and observe for at least 30 minutes after infusion.
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (2)
- Irinotecan + Sacituzumab govitecan Contraindicated
- Sacituzumab govitecan + Siponimod Major
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Sacituzumab govitecan : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- IV preparation and dilution
Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.
Autres médicaments de cette classe
Questions fréquentes
What is Sacituzumab govitecan used for?
Sacituzumab govitecan is a medicine in the class oncology. It is used for Breast cancer.
What side effects have been reported with Sacituzumab govitecan?
Decreased leukocyte count, Decreased neutrophil count, Decreased hemoglobin, Nausea, Diarrhea, Fatigue. Serious warning: Can cause severe, life-threatening or fatal neutropenia.
Can Sacituzumab govitecan be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause birth defects or embryo-fetal death: it contains SN-38, a genotoxic drug that targets dividing cells. No human or animal reproduction data. Check pregnancy status; use effective contraception during treatment and for 6 months after (men: 3 months). Breastfeeding: Unsafe. No human milk data. The antibody part is large and poorly absorbed, but the SN-38 payload may enter milk. US label: do not breastfeed during treatment and for 1 month after the last dose.
What does Sacituzumab govitecan interact with?
MediHelp lists 2 known interactions for Sacituzumab govitecan. Contraindicated: 1 · Major: 1. The most serious include Irinotecan, Siponimod.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
